Testing a targeted cancer drug for rare mutations across cancer types

Plain-English translation of NCT05770037 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing , a targeted cancer medication, in people of all ages who have cancers with a specific genetic change called ALK. The study includes rare cancers and cases where this genetic change appears in more common cancers. Researchers want to see if this medication can help control these cancers and potentially offer it through the NHS.

Many people with rare cancers or unusual genetic changes in common cancers have few treatment options. This trial aims to find out whether this medication can work for patients whose cancers have this specific genetic alteration, even if their cancer type is uncommon.

Do you qualify?

You likely qualify if…

you have been diagnosed with cancer that has a confirmed ALK genetic alteration detected by advanced genetic testing
you are aged 18 or older, or a child/teenager aged 10–17 who weighs at least 40 kg
you have adequate organ function (your liver, kidneys, and blood counts are healthy enough)
if you are a woman who can become pregnant, you agree to use effective birth control during the study and for three months after treatment ends
if you are a man whose partner can become pregnant, you agree to use barrier contraception during the study and for three months after treatment ends
you are willing to have a tissue biopsy or blood sample taken for testing

You likely don't qualify if…

you have been diagnosed with ALK-positive non-small cell lung cancer, which is excluded from this trial
you are a woman who is pregnant or breastfeeding
your organs (liver, kidneys, or blood counts) are not functioning well enough
you are unable or unwilling to have a tissue or blood sample taken
you weigh less than 40 kg (if you are a child or teenager)

What participation looks like

If you join, you'll start by having a biopsy or blood sample taken so researchers can confirm your genetic alteration. You'll then take the medication by mouth until your cancer stops responding, you experience unacceptable side effects, or you choose to stop. During treatment, you'll have regular blood tests and visits with your care team. After you finish the medication, you'll have follow-up visits every three months for two years to monitor how you're doing.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Testing a targeted cancer drug for rare mutations across cancer types

What is this trial?

Do you qualify?

What participation looks like

Trial locations